ZHU, BING-YAN,SIU, MICHAEL,MAGNUSON, STEVEN, R.,PASTOR, RICHARD,HAIYING, HE,YISONG, XIAO,JIFU, ZHENG,XING, XU,JUNPING, ZHAO,LIU, WENDY,LYSSIKATOS, JOSEPH P.,HURLEY, CHRISTOPHER A.,LIANG, JUN
申请号：
EP09767860
公开号：
EP2288260A4
申请日:
2009.06.19
申请国别(地区):
EP
年份:
2013
代理人:
摘要：
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
